Investment advice you can actually understand
Results 31 - 40 of 474 : Previous 1 2 3 4 5 6 7 8 9 Next
Get RSS Feed for Healthcare Providers and Services
A look back at the biggest stories this week in biotech and what they mean for investors.
Why WellPoint Is Ready to Recover
Market-trouncing returns could be written in this 5-Star.
3 Ingredients for an Obesity Drug Blockbuster
Can VIVUS's Qsymia Become a Billion Dollar Medication?
Is this meaningful? Or just another movement?
Qsymia made it to the market this year and met a tepid reaction. What's next?
Why Almost Family Is Poised to Outperform
Market-trouncing returns could be written in these five stars.
Keeping your portfolio healthy.
Affymax's drug treating anemia in dialysis patients was FDA approved this year, and is now a major threat to the competition. That has shares up nearly 270% for the year, making Affymax #11 on our list of the very best healthcare stocks of 2012.
A Year in Review: Hospital Companies and 1 to Watch in 2013
A yearly review of what worked and what didn't in the hospital sector, as well as one company to keep your eyes on next year.
Short-term uncertainty doesn't impact this insurer’s long-term appeal.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK